Santa Clara, CA) is the only percutaneous TMVR procedure approved by the Food and Drug Administration for mitral valve repair in the United States. 3 Atrial fibrillation (AF) is the most common form of cardiac arrhythmia in clinical practice, affecting 2.3-3.4% of the adult population and frequently seen among patients with MR (5% per year). 4, 5 Several studies have shown that AF results in an increased risk of stroke and all-cause mortality in the general population. 6, 7 Furthermore, AF was associated with increased surgical risk for mitral repair or replacement although other studies observed similar outcomes for AF and non-AF patients. 8, 9 AF may pose a technical challenge during TMVR given the irregularity of valve leaflet movements. However, conflicting results were reported on the impact of AF on TMVR outcomes. [10] [11] [12] [13] To the best of the author's knowledge, there is no current literature assessing the impact of AF on in-hospital outcomes of TMVR in a nationally representative US sample reflecting real practice. Since AF prevalence is increasing, a negative prognostic impact of AF on TMVR outcomes has imperative clinical implications. 4 We sought to determine the prevalence of AF in patients who underwent TMVR with MitraClip in the United States and to appraise the impact of AF on in-hospital outcomes of patients undergoing TMVR using a large-scale US database.
2 | METHODS
| Study population
Our study was conducted using the National Inpatient Sample (NIS) Modification (ICD-9-CM) codes to identify the study variables. All the patients who underwent TMVR (age ≥18 years) from 2011 to 2014
were included (procedure codes of 35.97) were included. The approach of identifying TMVR hospitalizations according to ICD-9-CM codes have been used in prior work examining the NIS. 15 The included TMVR patients were then stratified into two major groups based on the presence or absence of AF. The presence of AF was based on ICD-9-CM code 427.31, which has been previously validated. 16 Given the retrospective nature of this study, the Wayne State Institutional Review Board did not require informed consent for this study.
| Baseline characteristic and outcome variables
The primary outcome was the impact of AF on inpatient mortality. 
| Statistical analysis
We used the hospital trend/discharge weight provided by AHRQ to generate national estimates including sum, rates, and averages. Chi- Table S1 ). This model demonstrated very good discrimination (C-statistic = 0.79) and calibration (P-value for Hosmer-Lemeshow goodness of fit test = 0.09). Success of matching was assessed based on the standardized differences in patient-and hospital-level covariates between the two groups. 19 Finally, a hierarchical model with unique hospital identification number as a random effect in the model was used to compare clinical outcomes between the two groups: mixed-effect logistic model to estimate odds ratios for binary outcomes while linear mixed model to evaluate differences in cost and length of stay. All the analyses were performed using STATA 14 (StataCorp, College Station, TX) with a level of significance set at 0.05.
| RESULTS
The study population included 1026 patients from the national inpatient sample registry; all had TMVR between 2011 and 2014. Of these (43.82% women and 74.43 ± 12.60 years old), the prevalence of pre-existing atrial fibrillation was approximately 56%. The mean age for the TMVR group with atrial fibrillation was 76.60 ± 10.68 
| DISCUSSION
In the present analysis of the US national inpatient database, we evaluated the potential effects of atrial fibrillation on in-hospital outcomes of TMVR with the MitraClip system. Our study revealed three important findings. First, the prevalence of AF among patients undergoing TMVR with MitraClip in the United States is around 56%.
Second, the presence of AF did not increase the in-hospital mortality after TMVR. Third, the safety profile of TMVR and utilization of resources (hospitalization costs and length of stay) among AF patients was comparable to the Non-AF patients. Therefore, AF does not carry a prohibitive procedural risk for patients being considered for TMVR.
AF was more frequent in our study than in EVEREST II trial or the TRAMI registry-based study by Jabs et al. 10, 12 In contrast with the EVEREST II trial, and Jabs et al study, both cohorts (with and without AF) were equally likely to have advanced cardiac and non-cardiac comorbidities. 10 Furthermore, a propensity-matching model was used to mitigate potential confounding, reduce the impact of selection bias and to derive two matched cohorts for comparative outcomes analysis.
In our study, in-hospital mortality and TMVR complications rates were similar in both subgroups with no statistical difference detected. The relatively low post-TMVR adverse event rate underlines the safety of the MitraClip procedure in "real-world" practice regardless of the initial rhythm. Furthermore, our study confirms findings from the EVEREST II trial and previous studies by Hermann et al, Jabs et al, and Velu et al. 10, 12, 13 Previous literature has described the risk of thrombus formation after MitraClip implantation given the prothrombotic intracardiac device utilization and the dramatic hemodynamic changes after TMVR. 20 However, our study demonstrated that AF was not associated with increased in-hospital risk of stroke. The previous findings are in agreement with Velu et al and Jabs et al studies, where stroke incidence was not significantly different regardless of the baseline rhythm after 22 and 12 months follow-ups, respectively. Although, AF is a well-known risk factor for embolic stroke, we speculated that hospitalized patients with AF were likely receiving anticoagulation treatment for AF. However, our study lacks information on anticoagulant agent use; therefore, the precise reason underlying the previous result is not entirely apparent. Our study has several limitations that deserve to be emphasized.
First, our data are derived from a retrospective registry; thus, we cannot identify different types of AF (permanent, persistent, or paroxysmal). Furthermore, our database lacked information on rate control, the pattern of anticoagulation, laboratory results and echocardiographic parameters (eg, ejection fraction). Therefore, the impact of the previous variables on outcomes cannot be determined. Despite lacking this granularity, analysis of large administrative databases is a useful resource to understand the current real practice and for hypothesis-generation in the developing field of interventional valve therapy which was the primary goal of our study. Second in the NIS database, variables are identified using a coding system that is subject to coding errors and documentation disparities. However, the NIS data have been widely used and validated. 15 Lastly, our study is limited to the in-hospital outcomes;
follow-up data were not reported. However, strengths of this study included the nationally representative large sample size which involves multiple centers and populations across the United States and provides the most robust evidence to date. Furthermore, we matched the study patients using propensity score to control for the discrepancies in baseline characteristics.
| CONCLUSION
AF is a frequently encountered arrhythmia among patients undergoing TMVR with MitraClip. However, TMVR can be performed safely in the vast majority of patients, irrespective of baseline rhythm. Furthermore, prospective randomized trials to verify the observed outcome effects of atrial fibrillation among this subpopulation are warranted.
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